基于“伏风”理论探讨玉屏风散治疗长新冠致肺脾气虚型慢性荨麻疹
Exploring the Treatment of Chronic Urticaria with Lung-Spleen Qi Deficiency Type Induced by Long COVID Using Yupingfeng Powder Based on the “Fufeng” Theory
摘要: 新型冠状病毒感染(COVID-19)引发的系列后遗症日益受到医学界的重视,世界卫生组织(WHO)将感染新冠病毒三个月后持续存在、逐渐发展的新症状,或病程超过两个月且无法用其他病因解释的症状,统称为“长新冠综合征”(Post-COVID-19 Condition)。长新冠致荨麻疹是指COVID-19康复后发生的慢性荨麻疹(CU),表现为风团、瘙痒反复发作。文章旨在探讨“伏风”理论在长新冠致CU中的解释、应用及治疗方面的独特优势。“伏风”理论认为,“风邪内潜、正虚邪伏”是长新冠致CU的主要病机特点,其病因与“肺脾两虚、卫外不固”密切相关,治宜补益肺脾、祛风固表,在此基础上选用玉屏风散能达到良好的疗效。
Abstract: The series of sequelae triggered by the novel coronavirus infection (COVID-19) is increasingly gaining attention in the medical community. The World Health Organization (WHO) refers to the new symptoms that persist and gradually develop three months after infection with the novel coronavirus, or symptoms that last more than two months and cannot be explained by other causes, collectively as “Post-COVID-19 Syndrome”. Long COVID-induced chronic urticaria (CU) refers to the recurrent episodes of wheal and itching that occur after recovery from COVID-19. This article explores the unique advantages of the “Fufeng” Theory in explaining, applying, and treating CU caused by long COVID. The “Fufeng” Theory posits that “internal lurking wind evil and weak body resistance with latent evil” are the main pathological characteristics of CU caused by long COVID. Its etiology is closely related to “a deficiency of both the lung and spleen, and weak defensive qi”, and the treatment should focus on unifying the lung and spleen, dispelling wind, and strengthening the exterior. Based on this, using Yupingfeng powder can achieve good therapeutic effects.
文章引用:刘苡辰. 基于“伏风”理论探讨玉屏风散治疗长新冠致肺脾气虚型慢性荨麻疹[J]. 中医学, 2025, 14(4): 1392-1399. https://doi.org/10.12677/tcm.2025.144209

参考文献

[1] Allan, M., Lièvre, M., Laurenson-Schafer, H., de Barros, S., Jinnai, Y., Andrews, S., et al. (2022) The World Health Organization COVID-19 Surveillance Database. International Journal for Equity in Health, 21, Article No. 167. [Google Scholar] [CrossRef] [PubMed]
[2] Carfì, A., Bernabei, R. and Landi, F. (2020) Persistent Symptoms in Patients after Acute Covid-19. JAMA, 324, 603-605. [Google Scholar] [CrossRef] [PubMed]
[3] Koc, H.C., Xiao, J., Liu, W., Li, Y. and Chen, G. (2022) Long COVID and Its Management. International Journal of Biological Sciences, 18, 4768-4780. [Google Scholar] [CrossRef] [PubMed]
[4] Sanghvi, A.R. (2020) COVID‐19: An Overview for Dermatologists. International Journal of Dermatology, 59, 1437-1449. [Google Scholar] [CrossRef] [PubMed]
[5] Gottlieb, M. and Long, B. (2020) Dermatologic Manifestations and Complications of Covid-19. The American Journal of Emergency Medicine, 38, 1715-1721. [Google Scholar] [CrossRef] [PubMed]
[6] Darabi, A., Dehghanfard, M., Jozan, S., Tahmasebi, R., Movahed, A., Zamani, M., et al. (2021) Investigating the Association between Allergic Diseases and COVID-19 in 400 Iranian Patients. Allergologia et Immunopathologia, 49, 9-15. [Google Scholar] [CrossRef] [PubMed]
[7] Bermingham, W.H., Ardern‐Jones, M.R., Huissoon, A.P. and Krishna, M.T. (2021) Forewarned Is Forearmed: Chronic Spontaneous Urticaria as a Potential Risk to Effective Sars‐COV‐2 Vaccine Uptake and Global Public Health. British Journal of Dermatology, 185, 838-839. [Google Scholar] [CrossRef] [PubMed]
[8] 曹瑜, 郑辉烈, 刘智涛, 等. 1990-2019年中国荨麻疹疾病负担现状及趋势[J]. 中国皮肤性病学杂志, 2022, 36(8): 905-910+19.
[9] Akca, H.M. and Tuncer Kara, K. (2021) Evaluation of Urticaria Patients before and during the Period of the COVID‐19 Pandemic: A Retrospective Study. Dermatologic Therapy, 34, e14800. [Google Scholar] [CrossRef] [PubMed]
[10] Colmenero, I., Santonja, C., Alonso‐Riaño, M., Noguera‐Morel, L., Hernández‐Martín, A., Andina, D., et al. (2020) Sars‐Cov‐2 Endothelial Infection Causes COVID‐19 Chilblains: Histopathological, Immunohistochemical and Ultrastructural Study of Seven Paediatric Cases. British Journal of Dermatology, 183, 729-737. [Google Scholar] [CrossRef] [PubMed]
[11] Assil, S., Coléon, S., Dong, C., Décembre, E., Sherry, L., Allatif, O., et al. (2019) Plasmacytoid Dendritic Cells and Infected Cells Form an Interferogenic Synapse Required for Antiviral Responses. Cell Host & Microbe, 25, 730-745.e6. [Google Scholar] [CrossRef] [PubMed]
[12] Cappel, M.A., Cappel, J.A. and Wetter, D.A. (2021) Pernio (Chilblains), Sars-Cov-2, and COVID Toes Unified through Cutaneous and Systemic Mechanisms. Mayo Clinic Proceedings, 96, 989-1005. [Google Scholar] [CrossRef] [PubMed]
[13] Lim, K. and Staudt, L.M. (2013) Toll-Like Receptor Signaling. Cold Spring Harbor Perspectives in Biology, 5, a011247. [Google Scholar] [CrossRef] [PubMed]
[14] Barrat, F.J. and Su, L. (2019) A Pathogenic Role of Plasmacytoid Dendritic Cells in Autoimmunity and Chronic Viral Infection. Journal of Experimental Medicine, 216, 1974-1985. [Google Scholar] [CrossRef] [PubMed]
[15] Gallman, A.E. and Fassett, M.S. (2021) Cutaneous Pathology of COVID-19 as a Window into Immunologic Mechanisms of Disease. Dermatologic Clinics, 39, 533-543. [Google Scholar] [CrossRef] [PubMed]
[16] Zuo, Y., Estes, S.K., Ali, R.A., Gandhi, A.A., Yalavarthi, S., Shi, H., et al. (2020) Prothrombotic Autoantibodies in Serum from Patients Hospitalized with Covid-19. Science Translational Medicine, 12, Article No. 570. [Google Scholar] [CrossRef] [PubMed]
[17] Consiglio, C.R., Cotugno, N., Sardh, F., Pou, C., Amodio, D., Rodriguez, L., et al. (2020) The Immunology of Multisystem Inflammatory Syndrome in Children with Covid-19. Cell, 183, 968-981.e7. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, T., Feng, H., Zou, X. and Peng, S. (2022) Integrated Bioinformatics to Identify Potential Key Biomarkers for Covid-19-Related Chronic Urticaria. Frontiers in Immunology, 13, Article ID: 1054445. [Google Scholar] [CrossRef] [PubMed]
[19] 李经纬. 中医大辞典[J]. 医学研究杂志, 1999, 33(6): 10-11.
[20] 余峥瑶, 马丽俐. 从“伏风引触”论治特应性皮炎[J]. 浙江中医杂志, 2024, 59(5): 377-380.
[21] 宋天平, 薛凯元, 袁锐, 等. 基于“伏邪化气”理论浅谈荨麻疹的病因病机及治疗[J]. 环球中医药, 2025(2): 80-83.
[22] 申荣旻, 张妍, 王济, 等. 王琦教授调体治疗过敏性疾病方法探微[J]. 北京中医药大学学报, 2016, 39(1): 73-76.
[23] 郑文科, 张俊华, 杨丰文, 等. 中医药防治新型冠状病毒肺炎各地诊疗方案综合分析[J]. 中医杂志, 2020, 61(4): 277-280.
[24] 叶放, 吴勉华, 程海波, 等. 国医大师周仲瑛教授《新型冠状病毒肺炎中医辨治方案》解读[J]. 南京中医药大学学报, 2020, 36(2): 141-144.
[25] 汪彬彬, 潘杰, 陈绍斌, 等. 78例新型冠状病毒肺炎患者舌象的初步研究[J]. 江苏中医药, 2020, 52(4): 84-86.
[26] 李静, 王伟, 高琴. 荨麻疹的中医药认识及论治方法进展[J]. 中医研究, 2023, 36(1): 87-92.
[27] 汪津禾, 任建勋, 李亚琴, 等. 从“皮肤间风”辨治慢性荨麻疹经验[J]. 北京中医药, 2024, 43(11): 1327-1330.
[28] 陈思珏, 曹炜, 肖显俊, 等. 新冠疫情流行期间COVID-19感染与诱发皮肤病的关联[J]. 中华医院感染学杂志, 2024, 34(11): 1720-1724.
[29] 杨世英, 张光霁. 从风邪论治过敏性疾病[J]. 山东中医杂志, 2010, 29(1): 8-9.
[30] 薛枫, 吕晓东. 玉屏风散合麻黄附子细辛汤治疗过敏性鼻炎的研究进展[J]. 中国实用医药, 2022, 17(21): 184-187.
[31] 肖经苪, 陈伟炳, 闫小兵, 等. 玉屏风散重用黄芪方治疗慢性荨麻疹及其对患者免疫功能的临床研究[J]. 中医临床研究, 2020, 12(25): 82-84.
[32] 阎博华, 唐健元, 丁红, 等. 中医药促进新型冠状病毒肺炎恢复期康复临床研究方案[J]. 成都中医药大学学报, 2020, 43(1): 1-6.
[33] 郝峰, 魏爽, 胡晓阳, 等. 李冀运用玉屏风散加减验案三则[J]. 辽宁中医杂志, 2019, 46(10): 2189-2191.